Akademik Veri Yönetim Sistemi
Turkish Journal of Dermatology, cilt.19, sa.1, ss.41-60, 2025 (ESCI)
Mycosis fungoides (MF) is the most prevalent form of cutaneous T-cell lymphoma (CTCL). Tumor, lymph nodes, metastasis, and blood (TNMB) staging serves as the primary prognostic factor that significantly influences treatment strategies. The objectives of MF therapy are tailored to each patient, focusing on achieving adequate responses to alleviate symptoms and reducing the risk of progression. Continuing or maintenance therapies with low adverse effects are preferred to sustain disease control and enhance quality of life. This review is based on the latest international treatment guidelines from the European Organization for Research and Treatment of Cancer (EORTC), the National Comprehensive Cancer Network, and the British Association of Dermatologists in the United Kingdom Cutaneous Lymphoma Group. In early-stage MF, skin-directed treatments are effective, whereas systemic agents are required for early-stage refractory MF and advanced cases, including Sézary syndrome (SS). Biological and targeted therapies, as well as immunosuppressive treatments, are utilized in more severe cases, with new therapies for advanced disease currently under investigation in clinical trials. This review provides a comprehensive overview of the current treatment options for MF/SS by examining their mechanisms of action, efficacy, and side effects, thereby guiding clinicians in optimizing patient care.